Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

41.25
-0.0200-0.05%
Post-market: 41.250.00000.00%16:10 EDT
Volume:25.39K
Turnover:1.05M
Market Cap:1.06B
PE:- -
High:41.51
Open:41.37
Low:41.18
Close:41.27
52wk High:43.52
52wk Low:28.77
Shares:25.80M
Float Shares:25.80M
Volume Ratio:0.08
T/O Rate:0.10%
Dividend:0.29
Dividend Rate:0.70%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly Price Target Maintained with a $1500.00/Share by RBC Capital

Dow Jones
·
Yesterday

Merck Price Target Cut to $145.00/Share from $150.00 by RBC Capital

Dow Jones
·
Yesterday

Bristol Myers Stock is Rising on a Double Dose of Good News

Dow Jones
·
Yesterday

Bristol Phase 3 success with admilparant should send Contineum up, says Stifel

TIPRANKS
·
Yesterday

Bausch + Lomb CEO Saunders Departs, Chairman Appio Named Interim Chief

Reuters
·
Yesterday

Bristol-Myers Squibb: Zenbexus Phase III Validates Benefit but Competitive Pressures Keep Risk/Reward Balanced at Hold

TIPRANKS
·
Yesterday

Contineum Tumbles as Bristol's Partial Trial Win Raises Dose Doubts

Reuters
·
Yesterday

US Stocks on the MOVE-Salesforce, Brown & Brown, IonQ, Harmony Biosciences

Reuters
·
Yesterday

2 Brain-Computer Interface Stocks to Watch While Neuralink Stays Private

InvestorPlace
·
Yesterday

Bristol-Myers Squibb (BMY.US) Climbs in Pre-Market Trading! Two Experimental Drugs Deliver Positive Phase 3 Results, Accelerating Pipeline Diversification

Stock News
·
Yesterday

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Glaukos (GKOS)

TIPRANKS
·
Yesterday

US Equity Futures Mostly Flat Pre-Bell Ahead of Week of Earnings, Economic Data

MT Newswires Live
·
Yesterday

Bristol Myers Squibb Says RayzeBio's Phase 3 Study for RYZ101 Meets Primary Endpoint

MT Newswires Live
·
Yesterday

Merck & Company (MRK) Gets a Buy from Leerink Partners

TIPRANKS
·
Yesterday

Press Release: After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports

Dow Jones
·
Yesterday

Bristol Myers Cancer Therapy Meets Main Goal in Late-Stage Study

Reuters
·
Yesterday

Regenxbio to Host Investor Event on Sura-Vec Wet AMD Program Ahead of Pivotal Data Readout

Reuters
·
Yesterday

Options Volatility and Implied Earnings Moves This Week, October 13 – October 16, 2026

TIPRANKS
·
Yesterday

Bristol Myers reports ‘positive’ interim analysis of ACTION-1 trial by RayzeBio

TIPRANKS
·
Yesterday

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 Action-1 for Ryz101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with Gep-Nets

THOMSON REUTERS
·
Yesterday